Based on this info from PRR management.......
A maintenance style treatment like CVac™ would be the first
of its type in the market and would initially aim to take 10% of
this ovarian cancer market
• A 10% market share equates to approximately US$360m
• Cvac™ has indications across a multitude of cancers.
http://www.primabiomed.com.au/projects/prodDocuments/PRR%20ASX%20Investor%20Presentation%2021April%2009.pdf
My thoughts
Basic "Forecast"
600 million shares on issue
$30 million NPAT
Price Earnings Ratio 20
Earnings per share .05 cents
Share Price $1
My thoughts only Goodluck to holders.
what forecasts do we have for the share price?
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.8¢ |
Change
0.003(0.75%) |
Mkt cap ! $482.9M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $473.5K | 1.414M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14313 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 186878 | 20 |
View Market Depth
| Last trade - 12.37pm 26/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |